Viking Therapeutics, Inc.
VKTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VKTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with lead programs in obesity (VK2735) and non-alcoholic steatohepatitis (VK2809).
Key risk: No revenue and recurring losses
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.75B
Cash Runway
11.7 moLead Asset
VK2735 (Phase 3)
Next Catalyst
Phase3_Topline · Aug 1, 2027Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials · 1 catalyst for Viking Therapeutics, Inc..
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with lead programs in obesity (VK2735) and non-alcoholic steatohepatitis (VK2809).
- Viking Therapeutics has no approved products and has not generated any revenue to date [sec_mda · as of 2026-02-11].
- As of June 30, 2025, the company reported cash and equivalents of $125.8 million, with a net loss of $128.0 million for the six-month period [sec].
- The company's lead candidate, VK2735, is in Phase 3 development for obesity, with a topline readout expected in August 2027 [upcoming catalysts].
- Research and development expenses were $345.0 million in 2025, driven largely by clinical trials for VK2735, VK2809, and VK0214 [sec_mda · as of 2026-02-11].
- Viking believes it has sufficient capital to fund operations for at least the next 12 months as of mid-2025, but expects losses to increase materially as development progresses [sec_mda · as of 2026-07-29].
What works
- VK2735 has advanced to Phase 3 trials for obesity, a large and growing market, with a topline readout scheduled for August 2027 [upcoming catalysts].
- The company has a diversified pipeline including VK2809 for NASH and VK0214 for X-ALD, targeting multiple metabolic indications [sec_mda · as of 2026-02-11].
- Viking has maintained a strong balance sheet with $639.1 million in shareholders' equity as of June 30, 2025 [sec].
What to weigh
- Viking has no approved products and has never generated revenue, relying entirely on external financing to fund operations [sec_mda · as of 2026-02-11].
- The company reported a net loss of $128.0 million in the first half of 2025, and expects losses to increase materially as clinical programs expand [sec_mda · as of 2026-07-29].
- Viking will need to raise additional capital to complete its ongoing and planned trials, and such funding may not be available on acceptable terms [sec_mda · as of 2026-07-29].
- The company faces significant clinical and regulatory risks, including potential delays or failures in Phase 3 trials for VK2735 and other candidates [sec_mda · as of 2026-07-29].
From the filings
Quoted directly from source documents.
Viking has not generated any revenue to date.
“To date, we have not generated any revenue.”
SEC MD&A · February 11, 2026
Catalyst timeline
- 2027-08-01 · Phase 3 Topline for VK2735 — Topline results from a 78-week Phase 3 randomized, double-blind, placebo-controlled efficacy and safety study of VK2735 in obesity.
Risks & what to watch (4)›
Key risks
- No revenue and recurring losses — Viking has no approved products and has never generated revenue; net loss was $128.0M in H1 2025 [sec].
- Need for additional capital — The company expects losses to increase and will need to raise capital to fund trials; funding may not be available on acceptable terms [sec_mda · as of 2026-07-29].
- Clinical and regulatory uncertainty — Phase 3 trials for VK2735 and other candidates may face delays, negative results, or regulatory hurdles [sec_mda · as of 2026-07-29].
- Dependence on single lead candidate — VK2735 is the most advanced program; failure would significantly impact the company's prospects [sec_mda · as of 2026-02-11].
What to watch
- Phase 3 topline results for VK2735 in obesity, expected in August 2027 [upcoming catalysts].
- Updates on VK2809 Phase 2b VOYAGE trial for NASH, including biopsy data [sec_mda · as of 2026-02-11].
- Any partnership or licensing deals for VK5211 or other pipeline assets [sec_mda · as of 2025-02-26].
- Future capital raises or financing activities to support expanded clinical development [sec_mda · as of 2026-07-29].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Viking Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Viking Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
11.7 months
D/E 0.28 · 0% dilution
Lead: Phase 3
1 candidate
1 upcoming, next in ~336d
1 buy · 3 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
413
Total value held
$2.86B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 10,025,004 | $326.2M |
| blackrock, inc. | 6,880,290 | $223.9M |
| fmr llc | 6,024,753 | $196.0M |
| susquehanna international group, llp | 4,820,309 | $156.9M |
| vanguard portfolio management llc | 4,464,298 | $145.3M |
| two sigma investments, lp | 4,432,142 | $144.2M |
| state street corp | 4,395,557 | $143.0M |
| raymond james financial inc | 2,075,403 | $113.5M |
| morgan stanley | 3,013,928 | $98.1M |
| citadel advisors llc | 2,615,121 | $85.1M |
Showing top 10 of 413 institutional holders of Viking Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 21.9%
- Days to cover
- 9.7
- Shares short
- 24,006,215
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VKTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Viking Therapeutics, Inc.?
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with lead programs in obesity (VK2735) and non-alcoholic steatohepatitis (VK2809).
What is Viking Therapeutics, Inc.'s lead drug candidate?
Viking Therapeutics, Inc.'s most advanced tracked candidate is VK2735 (Phase 3) for Weight Loss.
What is Viking Therapeutics, Inc.'s next catalyst?
Viking Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 " — expected August 1, 2027.
Who is the CEO of Viking Therapeutics, Inc.?
Dr. Brian Lian Ph.D. is the chief executive officer of Viking Therapeutics, Inc. (VKTX).
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. (VKTX) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.